Geneva, May 28 -- International Clinical Trials Registry received information related to the study (ISRCTN96603462) titled 'Phase 1 Trial: Quotient Code QSC303303, Sponsor Code LMNL6511C1002' on May 2.
Study Type: Interventional
Study Design:
Two part single centre randomized double-blind study to assess biomarkers safety tolerability and pharmacokinetics (Other)
Primary Sponsor: Liminal BioSciences Limited
Condition:
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.
Other
Intervention:
The sponsor has confirmed that the trial meets the criteria for deferral of publicat...